Select Language:
A US biotech firm specializing in aesthetic technologies has recently introduced its agarose-based facial filler for facial reconstruction and contouring in China’s fast-expanding medical aesthetics industry, where there are limited domestic competitors.
The product, known as Algeness VL, received approval from China’s regulatory authority and is now distributed across China by China Biotics, its local partner. This filler is already accessible in over 40 countries and regions worldwide.
China’s market for injectable aesthetic treatments experienced a growth of over 150% in 2023 compared to 2018, reaching a value of approximately 67 billion yuan (around USD 9.4 billion), with an average annual growth rate of 21.1%. Projections from Frost & Sullivan, a US-based consulting firm, suggest this market could more than double by 2027, reaching approximately 147 billion yuan (roughly USD 20.6 billion).
So far, few Chinese companies have developed fillers based on agarose—the same material used in the product from Massachusetts. One notable exception is Shanghai-based Petal Biotechnology, which began establishing a production facility for similar products last month.
ChatGPT
Perplexity
Gemini AI
Grok AI
